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Abstract
Background: The criteria for organ sharing has developed a system that prioritizes
liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) who have
the highest risk of wait-list mortality. In some countries this model allows patients
only within the Milan Criteria (MC, defined by the presence of a single nodule up to
5 cm, up to three nodules none larger than 3 cm, with no evidence of extrahepatic
spread or macrovascular invasion) to be evaluated for liver transplantation. This
police implies that some patients with HCC slightly more advanced than those
allowed by the current strict selection criteria will be excluded, even though LT for
these patients might be associated with acceptable long-term outcomes.
Methods: We propose a mathematical approach to study the consequences of
relaxing the MC for patients with HCC that do not comply with the current rules for
inclusion in the transplantation candidate list. We consider overall 5-years survival
rates compatible with the ones reported in the literature. We calculate the best
strategy that would minimize the total mortality of the affected population, that is,
the total number of people in both groups of HCC patients that die after 5 years of
the implementation of the strategy, either by post-transplantation death or by death
due to the basic HCC. We illustrate the above analysis with a simulation of a
theoretical population of 1,500 HCC patients with tumor size exponentially. The
parameter λ obtained from the literature was equal to 0.3. As the total number of
patients in these real samples was 327 patients, this implied in an average size of
3.3 cm and a 95% confidence interval of [2.9; 3.7]. The total number of available livers
to be grafted was assumed to be 500.
Results: With 1500 patients in the waiting list and 500 grafts available we simulated
the total number of deaths in both transplanted and non-transplanted HCC patients
after 5 years as a function of the tumor size of transplanted patients. The total
number of deaths drops down monotonically with tumor size, reaching a minimum
at size equals to 7 cm, increasing from thereafter. With tumor size equals to 10 cm
the total mortality is equal to the 5 cm threshold of the Milan criteria.
Conclusion: We concluded that it is possible to include patients with tumor size up
to 10 cm without increasing the total mortality of this population.
Keywords: Liver transplantation, Hepatocellular carcinoma, Expanded criteria,
Modelling
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Introduction
Liver transplantation (LT) or hepatic transplantation is the replacement of a diseased
liver with a healthy liver from another person (allograft) [1]. The most commonly used
technique is orthotopic transplantation, in which the native liver is removed and re-
placed by the donor organ in the same anatomic location as the original liver. In a sub-
stantial proportion of patients with liver failure, orthotopic transplantation is the only
treatment option [2].
Liver failure occurs when large parts of the liver become damaged beyond repair and
the liver is no longer able to function. It may be caused by infections, toxic substances,
inherited diseases or malnutrition [3]. The chronic aggression of liver tissue by one of
the causes of liver failure can end up in primary hepatocellular carcinoma, a deadly
condition to which liver transplantation is the only option, with variable success rate of
a close to normal life after the surgery [4].
Within the past 5 years, the proportion of patients with HCC in waiting lists for LT
has increase dramatically: this proportion has reached more than 26% across Europe
and 34% in the United States [5].
The Milan Criteria, MC, is defined by the presence of a single nodule up to 5 cm, up
to three nodules none larger than 3 cm, with no evidence of extrahepatic spread or
macrovascular invasion. In the countries that adopt the MClaw allows patients only
within MC to be evaluated and considered for LT. This police implies that some pa-
tients with HCC slightly more advanced than those allowed by the current strict selec-
tion criteria will be excluded, even though LT for these patients might be associated
with acceptable long-term outcomes [6-8].
We propose a mathematical approach to study the consequences of relaxing the MC
for patients with HCC that do not comply with the current rules for inclusion in the
transplantation candidate list. We consider overall 5-years survival rates compatible
with the ones reported in the literature. We simulate our model in order to reproduce
what is known about the survival of the two groups of patients (those who comply with
the strict MC and those who do not) and calculate the best strategy that would
minimize the total mortality of the affected population, that is, the total number of
people in both group that dies after 5 years of the implementation of the strategy, ei-
ther by post-transplantation death or by death due to the basic HCC.
Methods
The Model
We assumed, as a model, that HCC patients present themselves along a short time
interval ΔT with tumors of variable sizes. We call this interval "at presentation". During
this time interval we assumed that N HCC patients are included in the transplantation
waiting list, and that F livers are available to these patients.
The model is based on four assumptions, namely,
1. the mortality rate of non-transplanted,αnt and transplanted,αt HCC patients are
described by the following ad hoc expressions:
αnt sð Þ ¼ α0 α1−e−δ1s
  ð1Þ
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And
αt sð Þ ¼ α0 þ δ2s ð2Þ
where δi(i=1,2) are the parameters, such that δ1>δ2and s is the size of the tumor. In
equation (1), when α1=2 the above mortality rates coincide for s=0. Since this is
necessary, we assume α1=2 for the rest of the paper. Note that s is the size of the
tumor at the moment patients get into the transplantation program. So, equations
(1) and (2) take into account the fact that tumors grow with time and so does the
mortality rates. This is included in a a rather cavalier manner in equations (1) and
(2) since the functional relationship of tumors growths related mortality with time
are not known.
Equations (1) and (2) are illustrated in Figure 1, in which it is shown the mortality
rates for both the transplanted and non-transplanted HCC patients as a function of
the tumor size s at presentation.
The probability of surviving after T years for non-transplanted and transplanted
patients, πnt(s) and πt(s), respectively, as a function of their tumor size, s, at the
time individuals are included in the transplantation program, is given by
πnt sð Þ ¼ exp −αntTð Þ ð3Þ
and
πt sð Þ ¼ exp −αtTð Þ ð4Þ
Equations (3) and (4) result in survival probabilities after T years that are in
agreement with data available in the literature. They were used to calculate the
form and parameters of equations (1) and (2).
2. the mortality of both transplanted and non-transplanted HCC patients is a
monotonically increasing function of tumor size at presentation (tumor size is,
therefore, taken as an indication of gravity).
3. the number of available livers to be grafted, F, is limited and always less than the
total number of HCC, N, who have transplantation indication; and finally,
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Figure 1 Mortality rates for transplanted (dotted line) and non-transplanted (solid line) HCC
patients. Results of the theoretical population analyzed, according to equations (1) and (2) with α0 = 0.048,
δ1 = 0.02 and δ2 = 0.006.
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4. the tumor size, s, at the time individuals are included in the transplantation
program, is distributed in the HCC population according to an exponential
distribution, such that the probability that a given HCC patient has tumor size s is
described by the probability density function (p.d.f.):
f s; λð Þ ¼ λe−λs ð5Þ
where λ is the rate parameter of the distribution. This implies that in a HCC
population, many individuals have tumor of small size and a very low number of
who present tumors of larger size. Again, this distribution of tumor size is that at
the moment the patients get into the transplantation program. The cumulative
distribution function (C.D.F.) is given by
F s; λð Þ ¼
Z s
0
λeλtdt ¼ 1−eλs ð6Þ
Equation (6) means the probability that a given HCC patient has tumor size equal
or less than s.
The exponential distribution has mean (expected value) equal to:
E s½  ¼ 1
λ
ð7Þ
and variance
Var s½  ¼ 1
λ2
ð8Þ
In Figure 2 we show the actual distribution of tumor size, fitted to an exponential dis-
tribution. The parameter λ in this case is equal to 0.3. As the total number of patients
in these samples was 327 patients, this implies in an average size of 3.3 cm and a 95%
confidence interval of [2.9; 3.7] [9-11].
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Figure 2 Frequency distribution of tumor size. Dots represent actual values from references [9-11] and
the line is the exponential fitting to the real data (R2 = 0.92). Parameter λ = 0.3 which implies in an average
tumor size of 3.3 cm.
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With the above assumptions we define p(s)ds as the proportion of individuals
with tumor size between s and s+ds; x(s)ds the proportion of transplanted patients
with tumor size between s and s+ds; and y(s)ds the proportion of non-transplanted
patients with tumor size between s and s+ds. These proportions are related such
that:
x sð Þ ¼ F
N
p sð Þ ð9Þ
and
y sð Þ ¼ 1− F
N
 
p sð Þ ð10Þ
Equations (9) and (10) can be interpreted as follows: a proportion p(s) of the HCC
patients has tumor size s, of which a fraction FN is transplanted and its complement
1− FN
 
is not transplanted, such that x(s) + y(s) = p(s). Note that, this was a particular
transplantation policy. For example, we could replace equation (9) and (10) byx sð Þ ¼ g
sð Þ FN p sð Þ and y sð Þ ¼ 1−g sð Þ FN
 
p sð Þ, where g(s) is some bias towards any eventual tumor
size preference. In this work, g(s)=1, meaning that all HCC patients have the same
chance of being transplanted (no bias). According to the Milan criteria,
g sð Þ ¼ 1 if s≤sM ¼ 5 cm
0 if s > sM ¼ 5 cm :

We then calculated:
1. If we choose to transplant every patient with any tumor size equal or less than a
critical tumor size, SF, then to guarantee that all patients with such tumor size less
than SF are transplanted (that is, all grafts are used), SF has to be defined as:
N
ZsF
0
p sð Þds ¼ F ð11Þ
or
sF ¼ −
log 1− FN
 
λ
ð12Þ
In other words, this means to choose a policy such that x(s≤SF)=p(s) and y(s≤SF)=0.
Equations (11) and (12) can be interpreted as follows:
ZsF
0
p sð Þdsis the fraction of the
population that has tumors of size equal or less than SF. Multiplied by the total
population N gives the total number of individuals that are transplanted, that is,
received all the liver grafts F. In other words, all available livers are used. The size
limit that guarantees that this happens, SF, is therefore calculated as a function of F
as in equation (12).
2. Hence, if not all patients with tumor size s are transplanted, for example, if we
choose to transplant x sð Þ ¼ FN p sð Þ and not transplant y sð Þ ¼ 1− FN
 
p sð Þ, then we
can choose to transplant all the patients with tumor size up to S0>SF.
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3. Using the Milan criteria (see above), the proportion of non-transplanted patients
with tumor size s below SM with respect to the total number of HCC patients at
presentation is:
pnt s < sMð Þ ¼
N 1−e−λsM
 
−F
N
if F < N 1−e−λsM
 
0 otherwise
8<
: ð13Þ
Equation (13) means that multiplying the proportion of patients with tumor size
equal or less than SM, 1-e
-λS
M by the total population of HCC, N, gives the number
of patients with tumors of size up to SM. This number minus the number of
available livers, divided by the total population size gives the proportion of non-
transplanted patients.
4. The proportion of transplanted patients with respect to the total number of HCC
patients at presentation, with tumor size s below SM:
pt s < sMð Þ ¼
F
N
if F < N 1−e−λsM
 
F
N
1−e−λsM
 
otherwise
8><
>: ð14Þ
Note that in the exceptional and unique case when SF=SM all the grafts are used
(see Models' Limitations for a more thorough discussion).
Equation (14) reflects the fact that a fraction FNof those individuals with tumor size
equal or less than SM is transplanted when the number of available livers F is less
than the number of individuals with tumor size greater than SM at presentation.
5. If the Milan criteria is obeyed, then the proportion of non-transplanted patients
with tumor size greater than SM:
pnt s > sMð Þ ¼ e−λsM ð15Þ
which is the minimum (if F is not enough to transplant up to SM)proportion of
individuals with tumor size greater than SM. According to the Milan criteria none
of those patients are transplanted, independently of F.
6. If the Milan criteria is not obeyed, then there is a proportion of transplanted
patients with tumor size greater than SM that could be transplanted. This
proportion is limited by the number of available livers, and it is:
pt s > sMð Þ ¼
Fe−λsM
N
if F > N 1−e−λsM
 
0 otherwise
8<
: ð16Þ
In this situation, the proportion of non-transplanted is given by:
pt s > sMð Þ ¼
e−λsM if F < N 1−e−λsM
 
1−
F
N
otherwise
8<
: ð17Þ
Note that adding the proportion of non-transplanted individuals with tumor sizes
greater and less than SM gives1− FN. By the same token, adding the proportion of
transplanted individuals with tumor sizes greater and less than SM gives FN .
7. Now, we abandon the Milan criteria and transplant a proportion x sð Þ ¼ FN p sð Þof
individuals with tumor size up to S0 (variable), and compare the impact on the total
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mortality of HCC patients with the mortality resulting from adopting the Milan
criteria.
First we calculate the survival of transplanted patients (TS) with tumor size up to
S0 at a moment in time T after the patients presentation. The proportion of the
individuals with tumor size up to S0 at presentation is:
Zs0
0
λe−λsds ð18Þ
The proportion of patients at presentation who were transplanted and survived up
to T after the transplantation is:
Zs0
0
x sð Þe−αt sð ÞTds ¼ F
N
Zs0
0
λe−λse−αt sð ÞTds ð19Þ
Hence the total number of transplanted patients (TS) with tumor size up to S0 at
presentation and who survived up to time T is given by Equation (19) multiplied
by N:
TS ¼ N F
N
Zs0
0
λe−λse−αt sð ÞTds ¼ F
Zs0
0
λe−λse−αt sð ÞTds ð20Þ
1. 8. The number of patients with tumors up to tumor size S0 at presentation who
were not transplanted is
N
Zs0
0
y sð Þds ¼N
Zs0
0
1−
F
N
 
λe−λsds ð21Þ
and those who survived after time T are:
N
Zs0
0
1−
F
N
 
λe−λse−αnt sð ÞTds ð22Þ
Now, the number of patients with tumors greater than sizes0at presentation that
were not transplanted is:
N
Z∞
s0
p sð Þds ¼N
Z∞
s0
λe−λsds ð23Þ
and, among those, the survivors after time T are:
N
Z∞
s0
λe−λse−αnt sð ÞTds ð24Þ
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Hence, the total number of survivors after time T who were not transplanted is:
NTS ¼ N
Zs0
0
1−
F
N
 
λe−λse−αnt sð ÞTdsþ N
Z∞
s0
λe−λse−αnt sð ÞTds ð25Þ
9. Therefore, the Total Survival is obtained by adding equations (20) and (25):
Survivors ¼ F
Zs0
0
λe−λse−αt sð ÞTdsþ N
Zs0
0
1−
F
N
 
λe−λse−αnt sð ÞTdsþ N
Z∞
s0
λe−λse−αnt sð ÞTds
ð26Þ
10.Finally, the Total Mortality is given by
M s0ð Þ ¼ N− F
Zs0
0
λe−λse−αt sð ÞTdsþ N
Zs0
0
1−
F
N
 
λe−λse−αnt sð ÞTdsþ N
Z∞
s0
λe−λse−αnt sð ÞTds
2
4
3
5
ð27Þ
11.Now, to calculate the optimal transplantation strategy, we determine the tumor size
that can be transplanted and find either s such that
min[M(s)] or s such that M(s)=M(SM).
Results
We illustrate the above analysis for a simulation of a theoretical population of 1,500
HCC patients with tumor size parameter distribution of λ equal to 0.3. As the total
number of patients in the real samples from which data was retrieved was 327 patients,
this implied in an average size of 3.3 cm and a 95% confidence interval of [2.9; 3.7]
[9-11]. The total number of available livers to be grafted was assumed to be 500. With
this, we simulated the total number of deaths in both transplanted and non-
transplanted HCC patients after 5 years as a function of the tumor size of transplanted
patients. The result is shown in Figure 3.
Figure 2 shows the total mortality in the HCC patients cohort, including those
transplanted and those non-transplanted as well. The dotted line is a reference line: the
point where the mortality curve crosses it is the maximum tumor size that could be
transplanted without worsening the mortality in the list. Note that it is possible to in-
clude patients with tumor size up to 10 cm without increasing the total mortality of
this cohort.
Discussion
Some limitations of the model should be highlighted. Firstly, the most important, is the
fact that we considered a cohort of HCC patient isolated from the others causes of liver
failures and, therefore, from the waiting list. We circumvent this by assuming that the
500 available grafts were the equivalent of the number of livers typically allocated to
this kind of patients. Secondly, we arbitrarily assumed an exponential distribution for
the tumor size, although this is likely to be true. Thirdly, we assumed an ad hoc func-
tion for the death rates of transplanted and non-transplanted patients. However, assum-
ing any convex function for transplanted mortality rate as a function of tumor size, and
concave function for non-transplanted mortality rate would not qualitatively modify
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our results. Finally, on important consequence of the model, although not directly ob-
servable from the equations, is that by transplanting patients with tumor size greater
than SF, and, therefore, not transplanting a proportion of patients with tumor size less
than SF may result in a certain proportion of F livers that will not be used. This is a
consequence of equation (20) when T=0, that is, F
Zs0
0
λe−λsds ¼ F 1−e−λs0 . Note, how-
ever, that this would happen with any model that would not transplant all the patients
below a certain tumor size when there are enough livers available. Equation (14) illus-
trates that if there are enough livers then everybody with tumour size below SM would
be transplanted. This should not be taken as an advantage of MC because (as can be
seen from equation (14)) transplanting every patient in need is an exceptional case, that
occurs when SM=SF. Remember that SM is determined by law and SF by chance, de-
pending on the number of available grafts F, the incidence of HCC, N and the distribu-
tion of tumour size in these patients at presentation.
The MELD (Model for End stage Liver Disease) score has been selected as the most
clinically appropriate tool for accurately predicting mortality in patients with chronic
liver diseases [1,12-14]. However, the MELD score does not accurately predict survival
in some patients, such as those with HCC. To enable patient with HCC to undergo LT
at a rate similar to that for patients without HCC, additional points based on the num-
ber and size of the HCC nodules are assigned to patients with HCC on the waiting list;
the intention is to match the risk of death for those with similar MELD scores but no
HCC [15]. With this strategy, HCC patients have easier access to transplantation than
non-HCC ones. In addition, this system does not allow for a dynamic assessment,
which would be required to picture the current use of local tumor treatment.
Because of the paucity of donors organs, efforts have been made to optimize the ef-
fectiveness of LT through the application of strict criteria for selecting patients who
have the greatest likelihood of prolonged survival after surgery. LT is a well-established
treatment in a subset of patients with cirrhosis and HCC. The Milan criteria (single
nodule up to 5 cm, up to three nodules none larger than 3 cm, with no evidence of
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Figure 3 Total mortality after 5 years comprising both transplanted and non-transplanted HCC
patients in a 1,500 theoretical population. We show only what happens when individuals with tumor
size greater that the strict Milan criteria (5 cm).
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extrahepatic spread or macrovascular invasion) have been traditionally accepted as
standard of care. The introduction of MC improved 5 year survival post-LT for HCC
from below 50% to greater than 70% [16,17]. However, some groups have proposed that
these criteria are too restrictive, and exclude some patients from transplantation who
might benefit from this procedure. Transplanting patients with tumors beyond the
established criteria falls into two categories, those whose tumors are beyond the MC at
presentation without the use of treatment prior to transplantation (expanded criteria),
and those in whom treatment allows the MC to be fulfilled (down-staging). Currently,
however, there is no international consensus regarding these approaches in clinical
practice, as different populations such as Europeans, Americans or Asians have distinct
HCC evolution and this should greatly influence the establishment of transplantation
criteria [8,12].
Expanded Milan criteria (EMC) can be defined by the use of LT in recipients with tu-
mors beyond the MC. The first description was published in 2001 by the group of the
University of California, San Francisco (UCSF) [18]. In their study, 70 HCC-patients
who underwent LT were retrospectively evaluated on the basis of explant analysis, not
pre-transplant radiology. In the 60 cases with either a single nodule up to 6.5 cm, or up
to three nodules none larger than 4.5 cm, and total tumor diameter no more than 8 cm
the 5-year overall survival was 75.2%. Forty-six out of the 60 patients (76%) had tumors
that were within the MC and these had a 5-year survival of 72%. Subsequently, a num-
ber of different EMC proposals have been described [19,20].
To optimize allocation of donated organs, Volk et al. [21] created a mathematical
model focused on the lowest acceptable survival rate after LT for which the use of
donor organs of standard quality could be justified and revealed that unless a 5-year
survival of at least 61% could be achieved, performing LT for patients with tumors be-
yond MC put other patients without HCC at a risk of dying without LT [21]. This sur-
vival rate may increase to 71% in regions with severe organ shortage and reduced 25%
in regions where shortage is not so acute. Samuel et al. [22] comment that this study
has several limitations because it did not evaluate the use of donor organs of marginal
quality, and it assumed that long-term survival after LT does not vary as a function of
preoperative MELD score.
More recently, Tosa et al. [23] used a competitive risk model assessment, and, suggest
a model for comparing the opportunities of receiving a graft for both HCC (deMELD)
and non-HCC (MELD) patients on a common waiting list concluding that the alloca-
tion of deMELD (drop-out risk scores to HCC) has the potential to allow for a dynamic
and combined comparison of opportunities to receive a graft for HCC and non-HCC
patients on a common waiting list.
There is a lack of studies addressing these issues in the literature. In addition, the ex-
trapolation of these findings to routine clinical practice is limited by our inability to ac-
curately predict survival after LT for individual patients with HCC who do not meet
the MC.
Finally, the methodology used in this paper explored the theoretical outcomes of
HCC patients as a function of tumor size for transplantation, violating the limit pro-
posed by the Milan Criterion. The model proposed was based on the calculation of
mortality as a function of tumor size. Other indicators of clinical outcomes could be
used instead of tumor size with the same model. In addition, other methods of analysis
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could be used to optimize the number of patients that could be transplanted, such as
game theory [24] or non-binary logics like the theory of fuzzy sets [25-27]. This, how-
ever, will be subject of future work.
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